These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 32917780)
1. Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780 [TBL] [Abstract][Full Text] [Related]
2. PET imaging of colon cancer CD73 expression using cysteine site-specific Jung KH; Kim M; Jung HJ; Koo HJ; Kim JL; Lee H; Lee KH Sci Rep; 2024 Aug; 14(1):17994. PubMed ID: 39097625 [TBL] [Abstract][Full Text] [Related]
3. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647 [TBL] [Abstract][Full Text] [Related]
4. Immuno-PET Imaging of Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426 [TBL] [Abstract][Full Text] [Related]
5. Preclinical PET imaging with the novel human antibody Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343 [TBL] [Abstract][Full Text] [Related]
6. Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549 [TBL] [Abstract][Full Text] [Related]
7. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023 [TBL] [Abstract][Full Text] [Related]
8. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891 [TBL] [Abstract][Full Text] [Related]
9. Jung KH; Lee JH; Kim M; Cho YS; Lee KH Mol Imaging; 2022; 2022():5916692. PubMed ID: 35250391 [TBL] [Abstract][Full Text] [Related]
10. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma. Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281 [TBL] [Abstract][Full Text] [Related]
11. Probody Therapeutic Design of Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313 [TBL] [Abstract][Full Text] [Related]
12. Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by Jung KH; Lee JH; Kim M; Lee EJ; Cho YS; Lee KH Mol Imaging; 2022; 2022():4906934. PubMed ID: 35115900 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Chelator-to-Antibody Ratio on Development of Tsai SC; Farn SS; Lo WL; Ou Yang FY; Kang YC; Chen LC; Chen KT; Liao JW; Kung JY; Chen JT; Huang FJ Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138961 [No Abstract] [Full Text] [Related]
15. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742 [TBL] [Abstract][Full Text] [Related]
16. Radiolabelling and preclinical characterization of Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biologic Evaluation of a Novel Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984 [TBL] [Abstract][Full Text] [Related]
18. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047 [TBL] [Abstract][Full Text] [Related]
19. In Vivo Imaging of the Programmed Death Ligand 1 by González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151 [TBL] [Abstract][Full Text] [Related]